190900-21-1

Usage

Uses

Used in Pharmaceutical Synthesis:
1-N-Boc-5-oxo-1,4-diazepane serves as a key intermediate in the synthesis of various pharmaceuticals. Its Boc protecting group facilitates the controlled deprotection of amines, which is crucial for the synthesis of complex drug molecules.
Used in Organic Compounds Synthesis:
As a versatile building block, 1-N-Boc-5-oxo-1,4-diazepane is used in the preparation of a wide range of organic compounds. Its structural features allow for the creation of diverse functionalized derivatives, expanding the scope of organic chemistry.
Used in Drug Discovery:
1-N-Boc-5-oxo-1,4-diazepane's unique structural features and reactivity make 1-N-Boc-5-oxo-1,4-diazepane a valuable asset in drug discovery. It can be utilized to develop new therapeutic agents with potential applications in various medical fields.
Used in Organic Synthesis Research:
1-N-Boc-5-oxo-1,4-diazepane is employed in research to explore new synthetic pathways and methodologies. Its reactivity and the presence of the Boc protecting group make it an ideal candidate for studying novel reactions and mechanisms in organic synthesis.

InChI:InChI=1/C10H18N2O3/c1-10(2,3)15-9(14)12-6-4-8(13)11-5-7-12/h4-7H2,1-3H3,(H,11,13)

Upstream product

• 34376-54-0 [1,4]diazepan-5-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 190900-20-0 hexahydro-(5H)-1,4-diazepine-5-one acetic acid salt 
• 150008-24-5 tert-butyl 4-(hydroxyimino)piperidine-1-carboxylate 
• 99822-50-1 1,4-diazapen-2-one 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 55186-89-5 1-benzyl-1,4-diazepan-5-one 

Downstream Products

• 911494-00-3 tert-butyl 5-thioxo-1,4-diazepane-1-carboxylate 
• 34376-54-0 [1,4]diazepan-5-one 

Relevant academic research and scientific papers

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

1,2,4 -TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA

This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF

The invention relates to compounds of general formula (I) wherein R1,R2, R3, R4, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use -alone or in

An efficient catalytic method for the Beckmann rearrangement of ketoximes to amides and aldoximes to nitriles mediated by propylphosphonic anhydride (T3P)

An efficient method for the Beckmann rearrangement of ketoximes to amides mediated by a catalytic amount (15 mol %) of propylphosphonic anhydride (T3P) is described. Aldoximes underwent second order Beckmann rearrangement to provide the corresponding nitriles in excellent yields on reacting with T3P (15 mol %) at room temperature. The main advantages of this environmentally friendly protocol include procedural simplicity, and particularly ease of isolation of the products.

HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF

Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

Routes to HIV-integrase inhibitors: efficient synthesis of bicyclic pyrimidones by ring expansion or amination at a benzylic position

Ring expansion of [6,6] bicyclic pyrimidones led, through an aziridinium intermediate, to potent HIV-integrase inhibitors with a [7,6] core. A more flexible and diversity-oriented synthesis of functionalized pyrimidohexahydrodiazepines was then developed;

DIAZEPINE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS

The present invention relates to a new class of oxazolidinone derivatives, to their use as antibacterial agents, to pharmaceutical compositions containing these compounds and to methods for their preparation.

Aminobenzoxazoles as therapeutic agents

A compound of Formula (I), wherein the substituents are as defined herein, which are useful as kinase inhibitors.

PYRROLOPYRIMIDINE DERIVATIVE

A pyrrolo[3,2-d]pyrimidine derivative represented by the formula (I) or a pharamaceutically acceptable salt of the derivative. The derivative or salt is useful as a GSK-3 inhibitor.

Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases

The preparation and SAR of a series of iNOS inhibitors leading to the most potent compound, incorporating a (1,4)-5-imino thiazepane (R = n-Pr) is disclosed. A series of 3- and 5-imino analogs from oxazepane, thiazepane, and diazepane was prepared and eva